Payment overview · 2025
General Payments
$193.58
5 reported records · 4 companies
Healthcare provider profile · identity verified
Salvador Cuellar Hernandez, MD
Allopathic & Osteopathic Physicians|Family Medicine · INDIO, CA · NPI 1477819829
Verified facts
What the public records show
CMS Open Payments records show Salvador Cuellar Hernandez, MD received $193.58 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.70 | 59.2% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $41.10 | 21.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.11 | 9.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.67 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.58 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $114.70 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $41.10 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1602 | 510 |
| Losartan Potassium | Losartan Potassium | 1078 | 330 |
| Metformin Hcl | Metformin Hcl | 842 | 254 |
| Amlodipine Besylate | Amlodipine Besylate | 584 | 209 |
| Lisinopril | Lisinopril | 557 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 442 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 432 | 130 |
| Alendronate Sodium | Alendronate Sodium | 399 | 134 |
| Gabapentin | Gabapentin | 372 | 141 |
| Furosemide | Furosemide | 252 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 232 | 70 |
| Pioglitazone Hcl | Pioglitazone Hcl | 224 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 72 |
| Famotidine | Famotidine | 197 | 68 |
| Simvastatin | Simvastatin | 195 | 64 |
| Ezetimibe | Ezetimibe | 184 | 71 |
| Januvia | Sitagliptin Phosphate | 177 | 49 |
| Naproxen | Naproxen | 164 | 92 |
| Donepezil Hcl | Donepezil Hcl | 152 | 39 |
| Jardiance | Empagliflozin | 141 | 41 |
| Valsartan | Valsartan | 140 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 44 |
| Ibuprofen | Ibuprofen | 133 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 49 |
| Carvedilol | Carvedilol | 123 | 32 |
| Finasteride | Finasteride | 108 | 31 |
| Celecoxib | Celecoxib | 107 | 41 |
| Farxiga | Dapagliflozin Propanediol | 106 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 30 |
| Meclizine Hcl | Meclizine Hcl | 97 | 39 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 97 | 38 |
| Omeprazole | Omeprazole | 93 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 24 |
| Myrbetriq | Mirabegron | 82 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 35 |
| Potassium Chloride | Potassium Chloride | 76 | 25 |
| Allopurinol | Allopurinol | 73 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 60 | 15 |
| Trazodone Hcl | Trazodone Hcl | 60 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 16 |
| Sertraline Hcl | Sertraline Hcl | 58 | 18 |
| Clonidine Hcl | Clonidine Hcl | 55 | 25 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 18 |
| Buspirone Hcl | Buspirone Hcl | 54 | 21 |
| Eliquis | Apixaban | 53 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 20 |
| Nifedipine Er | Nifedipine | 52 | 20 |
| Atenolol | Atenolol | 50 | 13 |
| Metformin Hcl Er | Metformin Hcl | 49 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Montelukast Sodium | Montelukast Sodium | 46 | 16 |
| Spironolactone | Spironolactone | 46 | 16 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | 12 |
| Ozempic | Semaglutide | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 12 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | 14 |
| Pentoxifylline | Pentoxifylline | 33 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 21 |
| Nitroglycerin | Nitroglycerin | 28 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Glipizide | Glipizide | 26 | 14 |
| Meloxicam | Meloxicam | 24 | 20 |
| Ramelteon | Ramelteon | 23 | 13 |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Gemtesa | Vibegron | 22 | 13 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Vascepa | Icosapent Ethyl | 21 | 12 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.58 · 5 records | Amgen Inc. | AREXVY, FFRct, OTEZLA, REPATHA, TRELEGY ELLIPTA, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error